Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
NCT ID NCT04923789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how long patients live without their cancer getting worse. The trial enrolled 100 adults aged 18 to 65 and tracked outcomes like survival and side effects over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous hematopoietic stem cell transplant followed by chimeric antigen receptor T (CAR-T) cell therapy
- What this could lead to
- If successful, this combination could offer a more effective treatment option for patients with hard-to-treat B-cell lymphoma that has come back or not responded to standard therapy.
- What could go wrong
- This is a single-center, non-randomized study with no control group, so results may not be generalizable. Both stem cell transplant and CAR-T therapy carry significant risks, including severe side effects like infection, organ damage, and immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Promising CAR-T therapy trial for lymphoma withdrawn before it began
- Experimental combo therapy for tough lymphoma shows promise but trial halted early
- Supercharged immune cells take on tough lymphoma
- New combo tackles tough lymphoma
- Triple-Target CAR T-Cells offer new hope for tough blood cancers